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D-Penicillamine (PA), a copper chelator, and one of the recommended drugs for treatment
of Wilson disease (WD) has been reported to worsen the symptoms of patients with
neurologic presentations. However, the cause of this paradoxical response has not been
fully elucidated and requires further investigations. Accordingly, we have studied the
in vitro effect of Copper (Cu) and/or PA treatment on human glioblastomaU251 cells as an
in vitro model of Cu cytotoxicity. Treatment of U251 cells with either Cu or PA exerted no
significant effect on their morphology, viability or ROS level. In contrast, co-treatment with
Cu-PA caused a decrease in viability, altered glutathione and ceruloplasmin expression
coupled with marked increase in ROS; depolarization of mitochondrial membrane
potential; and an increase in Sub G0 phase; along with alpha-Fodrin proteolysis. These
findings along with the absence of LDH release in these assays, suggest that combined
Cu-PA exposure induced apoptosis in U251 cells. In addition, pre-/or co-treatment
with antioxidants showed a protective effect, with catalase being more effective than
N-acetyl cysteine or trolox in restoring viability and reducing generated ROS levels. By
comparison, a similar analysis using other cell lines showed that rat PC12 cells were
resistant to Cu and/or PA treatment, while the neuroblastoma cell line SH-SY5Y was
sensitive to either compound alone, resulting in decreased viability and increased ROS
level. Taken together, this study shows that glioblastoma U251 cells provide a model for
Cu-PA cytotoxicity mediated by H2O2. We postulate that PA oxidation in presence of
Cu yields H2O2 which in turn permeates the plasma membrane and induced apoptosis.
However, other cell lines exhibited different responses to these treatments, potentially
providing a model for cell type- specific cytotoxic responses in the nervous system. The
sensitivity of different neural and glial cell types to Cu-PA treatment may therefore underlie
the neurologic worsening occurring in some PA-treated WD patients. Our results also
raise the possibility that the side effects of PA treatment might be reduced or prevented
by administering antioxidants.
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INTRODUCTION
Copper (Cu) is a ubiquitous trace element stored primarily in
the liver, but also present in other organs, such as the brain,
heart, kidney, and muscles (Osredkar and Sustar, 2011). It is an
essential micronutrient required for the catalytic and structural
properties of several important enzymes including: cytochrome
c oxidase (Yoshikawa et al., 1995; Tsukihara et al., 1996);
ceruloplasmin (Cp) (Kaplan and O’Halloran, 1996); dopamine-
β-monooxygenase (Rahman et al., 2009); Cu-Zn dependent
superoxide dismutase (Tainer et al., 1983); and peptidylglycine-
α-monooxygenase (Bousquet-Moore et al., 2010). However,
having unpaired electrons, excess copper generates highly
toxic hydroxyl and superoxide free radicals favoring lipid
peroxidation, mitochondrial impairment, DNA strand breakage,
and protein damage (Halliwell and Gutteridge, 1990; Fraga,
2005). Thus, the in vivo regulation of copper levels in biological
systems is under strict control through the actions of copper
transporters and chaperones (Harris, 2000; Madsen and Gitlin,
2007; Robinson and Winge, 2010; Jiang et al., 2013).
Defects in the ATP7B gene encoding a copper transporting
Cu-ATPase disrupt the homeostatic copper balance leading to
Wilson disease (WD), that is characterized by reduced biliary
Cu excretion, and impaired Cu incorporation into Cp (Cox and
Moore, 2002; de Bie et al., 2007; Lutsenko et al., 2007). Loading
of copper into apo-Cp occurs in the trans-Golgi network yielding
the active holo-Cp, the main plasma copper transporting protein
in circulation (Terada et al., 1998; Meyer et al., 2001). Hence,
failure of Cp-metallation and biliary copper excretion results in
copper accumulation primarily in the liver and brain leading to
hepatic cirrhosis and/or progressive basal ganglia degeneration
in WD patients (Madsen and Gitlin, 2007). The therapeutic
objective in the treatment of WD patients is to restore normal
copper homeostasis by either reducing the absorption of dietary
copper, or promoting its excretion (Gilroy et al., 2016).
D-Penicillamine (PA) (Figure 1A), first identified as a product
of penicillin hydrolysis, is the drug of choice to treatWD patients,
is marketed as Cuprimine or Depen (Stephenson and Roberson,
1960). Following its absorption through the gastrointestinal tract
(Van Caillie-Bertrand et al., 1985), PA binds excess copper via
its sulphydryl (SH) and amino (NH2) groups forming a non-
toxic ring complex (Figure 1B; Walshe, 2009). Furthermore, it
mobilizes intracellular copper into circulation for later excretion
in urine (McArdle et al., 1990). However, like any other
drug, PA has a number of side effects ranging from loss of
taste, headache, and abdominal pain to more serious problems
including hypersensitivity, suppression of bone marrow, skin
toxicity, nephro-toxicity, and autoimmune diseases (Scheinberg
et al., 1987; Czlonkowska et al., 1997).
More importantly, during the early stage of administration,
PA has been reported to result in severe deterioration in
about 50% of WD patients with neurologic symptoms with
minimal recovery even following drug discontinuation (Brewer
et al., 1987; Kalita et al., 2014). Being a pyridoxine (Vitamin
B6) antagonist, PA leads to the depletion of Vitamin B6,
forming a thiazolidine derivative (Walshe, 2011). Other studies
performed on toxic milk mice, WD animal model, reported
FIGURE 1 | (A) Structure of D-Penicillamine. (B) Structure of Cu-PA ring
complex.
that PA mobilization of serum and brain copper decrease the
protein-bound copper concentration and increase the oxidative
stress in the brain (Chen et al., 2012). Free and loosely
bound copper contributes to free radical production (Ogihara
et al., 1995) that perturbs antioxidants’ status and induces
neurodegenerative disorders in humans (Gilgun-Sherki et al.,
2001). However, evaluation of the systemic antioxidant potential
of WD patients treated with de-coppering agents, such as
PA, showed some improvement without restoring the normal
capacity of antioxidant parameters (Gromadzka et al., 2014). The
exact mechanisms underlying the worsening of the neurological
symptoms in PA-treated WD patients remain unclear and not
fully elucidated yet, requiring further investigations. Hence, our
study aims at assessing the effect of this copper chelating agent on
neural cell lines in vitro.
We hereby report the effect of Cu-PA co-treatment on
glioblastoma (U251), and neuroblastoma (SH-SY5Y) and
pheochromocytoma (PC12) cells. U251 cells were the most
sensitive to Cu-PA co-treatment while PC12 were least sensitive.
Concomitant to the decrease in viability of U251 cells, we
obtained a remarkable increase in ROS, a decrease in GSH
levels and increase in SubG0 (99%). While pre-treatment with
catalase reversed completely the marked apoptotic phenotype,
N-acetyl cysteine and Trolox ameliorated partially the Cu-PA
effect suggesting a key role for hydrogen peroxide (H2O2) in the
induced apoptosis. The Cu-PA effect was not specific to human
glioblastoma cell line only but was also shown in SH-SY5Y,
a neuroblastoma cell line. However, our preliminary results
with the latter cell line are suggestive of a different mechanism
than that seen in U251 cells. Findings of the current study have
identified potential targets for Cu-PA cytotoxicity and shed some
light on one of the underlying possible mechanisms that worsen
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the neurologic manifestations of D-PA treated WD patients.
In addition the demonstrated protective effects of antioxidants
(viability and ROS) pose the question as to whether antioxidant
supplements be part of therapeutic regimen when PA -treated
WD patients.
MATERIALS AND METHODS
Reagents and Antibodies
The following reagents were purchased from the indicated
suppliers: Sigma-Aldrich (Missouri, USA): Dulbecco’s Modified
Eagle’s medium (DMEM, and DMEM F12-HAM), Heat
Inactivated Horse Serum (HS) Donor Herd, Heat Inactivated
Fetal Bovine Serum (FBS), Ribonuclease A (RNase A) (cat#
R6513), Propidium Iodide (PI) (cat# P4170), Nitro-Blue-
Tetrazolium (NBT) Chloride, D-PA (cat# P4875), 0.4% Trypan
Blue Solution, Penicillin-Streptomycin (PS) mixture, Catalase,
NAC; Acros Organics (New Jersey, USA): Trolox 97%; Lonza
(Maryland, USA): Phosphate buffered saline (PBS) without
calcium and magnesium, 10X Trypsin; Biorad (California,
USA): Biorad protein assay kit, 4X Laemmli protein sample
buffer, Enhanced Chemi Luminescence’s Reagent (ECL) kit (cat#
1705060); Roche (Germany): Cytotoxicity Detection KitPLUS
for lactate dehydrogenase (LDH) release (cat# 04744934001),
Cell Proliferation Kit I for 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (cat#11465007001);
Immunochemistry Technologies LLC (Minnesota, USA):
MitoPTTM Kit for 5, 5′, 6, 6′–tetrachloro–1, 1′, 3, 3′–tetraethyl–
benzamidazolocarbocyanin iodide (JC-1) assay (cat# 911);
GE Healthcare (UK): Rainbow molecular ladder (RPN800E);
Abcam (UK): Fluorometric Glutathione (GSH) Detection Assay
Kit (ab65322), rabbit anti-ceruloplamin antibody (ab131220);
Enzo Life Sciences (New York, USA): mouse anti-α-Fodrin
antibody (BML-FG6090); Santa Cruz (California, USA): mouse
anti-GAPDH antibody (Sc-32233); Jackson ImmunoResearch
(Pennsylvania, USA):Peroxidase-conjugated goat anti-mouse
IgG (JIR-115-035-166), Peroxidase-conjugated goat anti-rabbit
IgG (JIR-111-035-003).
U251 Cell Culture and Treatment
U251 (formerly U373) human glioblastoma astrocytoma cells
(passages ranging from 20 to 45), provided as a gift by Dr.
Firas Kobeissy, were cultured in DMEM media supplemented
with 10% FBS, and 0.5% PS. Cells were seeded in 96-well plates
(0.8 × 104 cells/well/100µl media), 12-well plates (0.8 × 105
cells/well/1 mLmedia), or 100 mm petri-dishes (0.8 x 106 cells/10
mLmedia), incubated in a humidified 5%CO2 incubator at 37
◦C,
and then treated for 24 h with varying CuSO4 concentrations to
determine IC50. In addition, cells were treated with PA (250µM)
or a premix of Cu-PA (IC50, 250µM) to investigate the protective
effect of PA as a copper chelator.
MTT Cell Proliferation Assay
The viability of treated U251 cells was initially assessed in 96-
well plates using the colorimetric MTT cell proliferation assay
kit, following the supplier instructions. Briefly, 10µl of the yellow
tetrazolium salt was added to each well of control or treated cells
and incubated for 4 h at 37◦C. The formazan crystals formed
by the mitochondrial dehydrogenase of the metabolically active
cells were solubilized overnight by adding 100µl of solubilizing
reagent. The absorbance of the developed color was measured
using Multiskan EX ELISA reader at 595 nm. Cell viability was
expressed as percentage viability compared to a control of cells
treated with equal volume of vehicle (H2O).
Trypan Blue Exclusion Test
To confirm MTT results, the viability of Cu and/or PA treated
cells seeded in 100 mm petri-dishes was analyzed using trypan
blue exclusion test. While viable cells remain unstained, those
with damaged membrane stain blue. Treated cells, collected
following trypsinization, were centrifuged (swinging bucket
centrifuge) at 900 rpm for 5 min, re-suspended in 1 ml of
media, mixed with at a ratio of v/v with 0.4% trypan blue
solution, and then were counted under a light microscope using a
hemocytometer. The ratio of unstained cells to the total number
of cells (stained and unstained) was used to determine the
percentage of cell viability.
NBT Reduction Assay
Levels of intracellular reactive oxygen species (ROS) in Cu
and/or PA treated cells seeded in 96-well plates were determined
using NBT assay (Muñoz et al., 2000). Media of control and
treated cells was initially aspirated, followed by the addition
of NBT (100µl of 1 mg/ml) and incubation (1 h, 37◦C) in
a humidified 5% CO2 incubator. The wells were washed with
methanol (100µl), allowed to dry at room temperature, and
NBT salts reduced into formazan crystals were then solubilized
by the successive addition of KOH (120µl, 2 M) and DMSO
(140µl). The intensity of the developed blue-turquoise color was
quantified using Multiskan EX ELISA reader at 630 nm and
the percentage of reduced NBT was calculated from the ratio of
absorbance of treated to untreated control cells. The level of ROS
generated is inversely proportional to the level of NBT reduced.
LDH Release Assay
The extent of necrosis in cells treated with PA and/or Cu was
examined in 96-well plates using the Cytotoxicity Detection
kitPLUS following the manufacturer’s instructions. Rate of cell
lysis was determined by colorimetric measure (at 490 nm using
Multiskan ELISA) of the amount of LDH released from the
cells into the culture medium. The percentage LDH release was
quantified as described by the cytotoxicity kit manual using
suggested proper controls.
Fluorescent MitoPT-JC1 Assay
The effect of Cu and/or PA on the mitochondrial membrane
potential was examined using the cell permeable lipophilic
fluorescent JC-1 dye of MitoPT-JC1 assay. Entry of the
positively charged JC-1 is favored by the negatively charged
non-apoptotic mitochondria yielding red-orange fluorescent
aggregates; whereas in compromised cells, JC-1 gets dispersed
throughout the cell forming green fluorescent monomers.
Treated U251 cells, seeded in 12-well plates on sterile glass cover
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slips, were stained for 15 min at 37◦C with 300µl of 1X MitoPT-
JC1 stain solution, washed twice, and then visualized using
a fluorescent microscope (OLYMPUS; BH2-RFCA) containing
long band path emission filters Ex 490 nm and Em > 510 nm.
Images were taken by OLYMPUS DP71 camera using the
DP controller (OLYMPUS, 2001-2006; 3.1.1.267) acquisition
software.
Cell Cycle Analysis
The effect of the treatments on cell cycle progression was
assessed by flow cytometry. The fluorescence intensity of PI-
stained DNA reflects the DNA content of a cell, which determines
the proportion of cells in the different cell cycle phases. U251
cells were seeded in 100mm petri-dishes, treated with Cu, PA,
or Cu-PA for 24 h, trypsinized, centrifuged (swinging bucket
centrifuge), washed with PBS, fixed in 70% ethanol (1 h,−20◦C),
then allowed to warm room temperature, washed with PBS, re-
suspended in RNase A (100µl of 200µg/ml), and incubated
(1 h, 37◦C). Cells were later centrifuged (mini spin centrifuge),
re-suspended in PBS (350µl), and stained by PI (20µl of
1mg/mL) for 10min in the dark, as described byWlodkowic et al.
(2009). The PI-elicited fluorescence was measured using Guava
EasyCyte8 Flow Cytometer. Each sample was collected as 5000
ungated events and the corresponding cell cycle distribution,
according to the DNA content, was then determined.
Glutathione Level Determination
The total intracellular GSH level in PA and/or Cu treated cells
was assessed using fluorometric glutathione detection assay kit.
Treated and untreated U251 cells, seeded in 100mm petri-dishes,
were collected in eppendorf tubes by centrifugation (700 g,
5min–mini spin centrifuge), lysed (100µl of the kit’s cell lysis
buffer), incubated on ice (10min), and centrifuged at top speed
(13400 rpm, 10 min–mini spin centrifuge). Different volumes of
the obtained supernatant, adjusted to a final volume of 100µl
with lysis buffer, were introduced in clear-bottom 96-well plates,
followed by the consecutive addition of Glutathione S-transferase
(2µL) and monochlorobimane (2µL), and incubation for 1 h
(37◦C). Fluorescence was measured using Fluoroscan Ascent FL
at Ex/Em = 360 ± 20 /460 ± 20 nm. GSH levels in Cu, PA, or
Cu-PA treated cells were compared to those of untreated control
cells.
Western Blot Analysis
Western blot analysis was performed to determine the expression
of Cp level and to assess the pro-apoptotic marker cleavage
of α-Fodrin in Cu, PA, Cu-PA treated cells. Cells were
harvested and lysed by Triton 1%-SHT (Sucrose 250mM–
Hepes 10mM–Tris 50mM) lysis buffer (pH = 7.4). Protein
concentration was quantified (Bio-Rad Bradford assay) using a
UV-VIS scanning Spectrophotometer (SHIMADZU–UV–2101
PC). Following standard protocols, lysates containing 75–100µg
of protein were mixed with 4X laemmli buffer, boiled (10min),
and then were separated on 6% and 8% SDS-polyacrylamide gels
for α-Fodrin and Cp, respectively. Proteins were then transferred
onto a nitrocellulose membrane using BIORAD electro-transfer
set up. The membrane was then blocked with 10% fat-free
milk for 1 h, and immunoblotted overnight at 4◦C with the
appropriate primary antibody diluted as follows: anti-Cp (1:300),
anti-fodrin (1:500), and anti-GAPDH (1:1000). After three
washes (20min each) with Tris-buffered saline containing 0.1%
Tween 20, the membrane was incubated (1 h) with peroxidase-
conjugated secondary goat anti-mouse (1:5000) or anti-rabbit
(1:5000) and washed again three times. The protein expression
was visualized by the ECL reagent using RP X-OMAT processor
(Kodak, model M6B), scanned, and quantified using Image J
software. Fold expression was determined relative to the control
after normalizing for equal loading to their respective GAPDH
band.
Effect of Antioxidants on Cu-PA Treated
U251 Cells
The protective effect of antioxidants NAC/Trolox as well
as catalase enzyme on viability and ROS generation was
investigated using MTT cell proliferation assay and NBT
reduction, respectively. Seeding was performed according to
the respective assay conducted. U251 cells were co-treated with
catalase enzyme (500U) and Cu-PA for 24 h or were pretreated
with NAC (5mM) and Trolox (100µM) for 2 h, following which,
the pretreatment was aspirated and cells were treated with Cu-
PA for 24 h. To further assess whether the restoration of viability
and oxidative stress by catalase enzyme is dose dependent or
independent, varying concentrations of catalase ranging from 1
to 500U were used.
PC12 Cell Line
To study the effect of Cu and/or PA on neuronal cells, rat
pheochromocytoma cells (PC12) were used (passages ranging
from 20 to 45). Cells were cultured with DMEM media
supplemented with 10% FBS, 2.5% HS, and 0.5% PS, seeded in
96-well plates (1× 104 cells/well/100µl media), 12-well plates (1
× 105 cells/well/1mL media), or 100mm petri-dishes (1 × 106
cells/10mL media) and treated for 24 h with the appropriate
concentrations of CuSO4 and/or PA. All carried out experiments
on U251 cells were repeated on PC12 cell line.
SH-SY5Y Cell Lines
The effect of copper and/or PA on viability and reactive oxygen
species was also examined using the human neuroblastoma
SH-SY5Y cells cultured in DMEM Ham’s F-12 (sigma-Aldrich)
media supplemented with 10% FBS, and 1% PS. Cells were
seeded in: 96 well plates (5 × 103 cells/well/100 ul); and 6
well plates (1 × 105 cells/well/1ml), treated for 24 h with the
appropriate concentrations of CuSO4 and/or PA following which
NBT reduction assay, and viability (trypan blue) were performed,
respectively, as described in previous sections
Statistical Analysis
SPSS software was used to analyze data and determine
statistical significance. Both One-Way Anova and Independent
sample t-test were applied. For One-Way Anova analysis,
Post-hoc test (Bonferroni and Tukey) were used for multiple
comparisons. P < 0.05 is considered significant. For each
parameter tested, a set of at least three different experiments,
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unless otherwise mentioned, were done. Moreover, both inter-
categorical statistical significance and significance relative to
control were analyzed for each parameter. Data are represented
as the mean± standard error of the mean (SEM).
RESULTS
In vitro Cytotoxicity of CuSO4 and/or PA
The cytotoxicity of CuSO4 onU251 cells was initially investigated
using the MTT assay. We obtained a dose dependent decrease
in viability of 42 and 88% at 50µM and 200µM CuSO4
(p < 0.001) respectively (Supplementary Figure 1). Surprisingly
cytotoxicity assessed using Trypan blue exclusion assay showed
an insignificant or minimal decrease of 6% (p > 0.05) and 14%
(p < 0.05) in viability of U251 cells treated with 50 and 200µM
respectively (Figure 2).
On the other hand, PA, at 250µM, exerted a minimal effect
on the viability of U251 cells in MTT assay (15% cell death,
p < 0.001) and an insignificant effect in Trypan blue exclusion
test (10% cell death, p > 0.05), while co-treatment with Cu-PA
exhibited no protective effect, but led to a significant decrease in
the viability by 81% (p< 0.001) and 83% (p< 0.001) in both tests
respectively (Figure 2).
Membrane Integrity, Cell Morphology, and
Mitochondrial Membrane Potential in U251
No significant LDH release was noted in PA and/or CuSO4
treated cells, indicating no effect on membrane integrity of
U251 cells (data not shown). Further examination of U251
cells treated with CuSO4 (50 and 200µM) or PA (250µM)
showed no variation in the elongated morphology of the cells
(Figures 3B–D) compared to untreated control (Figure 3A).
However, co-treatment with Cu-PA resulted in significant
morphological changes in U251 cells assuming more of a
rounded morphology, indicating the initiation of apoptotic or
necrotic events (Figure 3E).
Examining further, possible alterations at the mitochondrial
level, compared to control cells (Figure 4A) we observed
partial, we observed partial depolarization in all PA-treated cells
(Figure 4D) but only in some of the Cu-treated U251 cells
(Figures 4B,C). However, we detected complete depolarization
of the mitochondrial membrane in all Cu-PA co-treated cells
(Figure 4E). Compared to Cu treated U251 cells (Supplementary
Figure 3) a significant round morphologic changes occurred in
cells treated for 15 h with Cu-PA (Supplementary Figure 4).
Cell Cycle Analysis of Treated U251 Cells
Figure 5 shows the average distribution of Cu and/or PA treated
cells in the subG0, G0/G1, S, and G2/M cell cycle phases. No
remarkable changes were obtained in cell cycle distribution of Cu
(50µM), or PA (250µM) treated U251 cells, (Figures 5A-b,d). A
minimal increase was obtained in subG0 (5%) and G2 M (8%)
phases in Cu (200µM) treated cells (Figure 5A-c). However, the
co-treatment of Cu-PA resulted in 98% increase in the subG0
(Figure 5B), indicating significant cell death (Figure 5A-e).
Oxidative Stress and Apoptosis in Cu
and/or PA Treated U251 Cells
Figure 6 shows no significant effect on ROS generation or
alteration in GSH level following 24-h treatment of U251
FIGURE 2 | MTT vs. Trypan blue exclusion assay: Comparative effect of Cu and/or PA on viability of U251 cells. U251 Cells (0.8 × 104) were treated with
CuSO4 (50µM, 200µM), PA (250µM), or Cu-PA (50–250µM) for 24 h. Data presented as % viability is the mean ± SEM of 18-determinations from 6-different
experiments using MTT assay, and of 3-determinations from 3- different experiments using Trypan blue exclusion assay. Asterisks on bars represent inter-categorical
statistical significance (each category with the preceding one), and those drawn upwards represent significance relative to the control. (***) correspond to P < 0.001.
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FIGURE 3 | Effect of treatment on morphology of U251 cells. The effect of (A) vehicle-water (control), (B) 50µM CuSO4, (C) 200µM CuSO4, (D) 250µM PA,
and (E) Cu-PA on morphology of U251 cells (0.8 × 106) seeded in petri dishes and treated for 24 h. Cells were examined under light microscope at 40X magnification.
cells with Cu (50 and 200µM) and PA (250µM) compared
to their respective control of untreated cells. However, co-
treatment of U251 cells with Cu-PA (50 and 250µM) decreased
NBT reduction by 50%, indicating thus an increase of 50%
in ROS level (p < 0.001) concomitant with a decrease in
GSH level of 49% (p < 0.001) characteristic of early stage
apoptosis.
To further confirm apoptosis and rule out necrosis, cleavage
of α-fodrin, an apoptotic marker was examined in Cu and/or
PA treated cells using western blot analysis. No fragmentation
was detected in U251 cells treated with PA or Cu alone
(Supplementary Figure 2); however, in Cu-PA co-treated U251
cells, α-Fodrin cleavage was induced resulting in many bands
detected at different KDa (Figure 7).
Protective Effect of Antioxidants on Cu-PA
Treated U251 Cells
Figure 8 shows the protective effect of antioxidants (NAC,
Trolox) and catalase enzyme on Cu-PA induced toxicity on
U251 cells. Pretreatment of U251 cells with NAC (5 mM),
or Trolox (100µM) for 2 h, restored partially the viability
of Cu-PA treated cells by 38% (p < 0.001) and 26% (p <
0.001), respectively; whereas co-treatment with catalase (500U)
restored the viability of Cu-PA treated cells by 73% (p <
0.001; Figure 8A). Similarly, pretreatment with NAC and Trolox
decreased the generation of ROS by 40% (p < 0.001) and
27% (p < 0.001), respectively; whereas co-treatment of catalase
completely restored the oxidative stress (50% decrease in ROS,
p < 0.001; Figure 8B). When different concentrations of catalase
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FIGURE 4 | Effect of CuSO4 and/or PA on mitochondrial membrane potential of U251 cells. Mitochondrial membrane depolarization was detected using Mito
PT JC-1 assay. The positively charged fluorescent probe JC-1 permeates the membrane of coupled non-apoptotic mitochondria that is negatively charged on the
matrix side yielding an orange red fluorescent aggregate. In compromised uncoupled mitochondria, JC-1 get dispersed throughout the cell forming a green monomer.
Representative images are for (A) control untreated, (B) 50µM CuSO4, (C) 200µM CuSO4, (D) 250µM PA, and (E) Cu-PA, treated U251 cells.
enzyme (1–500U) were co-treated with Cu-PA on U251 cells,
no significant difference was observed in their protective effect
on either viability (Figure 9A) or ROS generation (Figure 9B)
indicating that the reduction of hydrogen peroxide by catalase
is protective to the Cu-PA co-treatment.
Expression of Copper-Binding
Ceruloplasmin in U251 Cells
Compared to control, neither Cu (50 µM) nor PA (250 µM)
exerted any effect on the Cp expression level. However, when cells
were treated with Cu-PA, a significant decrease in Cp expression
level by 0.6-fold (p < 0.001) was obtained. The response of the
cells to Cu treatment (200 µM) was confirmed by the increase
(0.67-fold increase, p < 0.001) in Cp expression (Figure 10).
Effect of CuSO4 and/or PA on Neuronal
PC12 Cells
Similar viability profile to that of U251 was obtained in PC12 cells
treated with Cu or PA. However, Cu-PA co-treatment exerted a
different effect on PC12: no significant decrease in viability was
obtained by Trypan blue exclusion test, whereas 63% decrease
(p < 0.001) was reported using MTT assay (Figure 11A).
PA or Cu treatment exerted no effect on ROS generation
(Figure 11B), LDH release (Figure 11C), GSH level, cell
morphology, and cell cycle phases (data not shown). On the
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FIGURE 5 | Cell cycle analysis of U251 cells treated with CuSO4 and/or PA using Guava EasyCyte8 Flow Cytometer. Figure 6A is representative image of
one of three experiments: showing the cell cycle phases of U251 cells treated with: (A-a) vehicle water (A-b) 50µM CuSO4, (A-c) 200µM CuSO4, (A-d) 250µM PA,
and (A-e) Cu-PA. (B) is the average of 3 different experiments showing the distribution in the cell cycle phases: subG0,G0/G1, S, and G2/M.
other hand, the co-treatment slightly increased ROS generation
(Figure 11B) and LDH release (Figure 11C) by 16% each (p <
0.001), increased subG0 phase by 12%, but did not result in any
morphological change (Supplementary Figure 5) or variation in
GSH level. Furthermore, neither Cu nor PA exerted any effect on
the Cp expression level; however, Cu-PA co-treatment increased
(Figure 11E) the Cp expression (p< 0.001). At themitochondrial
level, partial depolarization of mitochondria was induced by PA
and Cu-PA while no effect was observed in Cu treated cells
(Figure 11D).
Effect of CuSO4 and/or PA on SH-SY5Y
Cells
We have also examined the effects of Cu and/or PA on
another neuronal cell line namely the neuroblastoma SH-SY5Y
cells. Morphological changes were observed with PA and Cu-
PA treated cells (Supplementary Figure 6). Similar to U251
cells, the viability of SH-SY5Y cells decreased significantly
(82%) following co-treatment with Cu-PA. However, unlike
U251 and PC12 cells, we obtained a significant decrease in
viability of 20 and 40% with Cu and PA treatment, respectively.
Further investigations on the effect of treatments on ROS
level exhibited a different profile from those obtained with
U251 and PC12 cells. Treatment of SH-5H5Y with Cu or
PA caused a decrease in NBT reduction of 28 and 34%
respectively indicating that these cells are more sensitive to PA
treatment alone, unlike U251 and PC12; co-treatment with Cu-
PA resulted in 41% decrease in NBT reduction (Supplementary
Figures 7A, B).
DISCUSSION
D-Penicillamine (PA) is a commonly used drug to treat WD,
as well as heavy metal poisoning, cysteinuria, rheumatoid
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FIGURE 6 | Effect of CuSO4 and/or PA treated U251 cells on ROS and GSH levels. The levels of ROS generated and GSH were determined in U251 treated
cells using NBT reduction assay and the fluorometric glutathione detection kit respectively. Data presented is the mean ± SEM of 9-determinations from 3-different
experiments for ROS and of 6-determinations from 3-different experiments for GSH levels. Asterisks on bars represent inter-categorical statistical significance (each
category with the preceding one), and those drawn upwards represent significance relative to the control. (*) and (***) correspond to P < 0.05 and 0.001 respectively.
arthritis, primary biliary cirrhosis, and progressive systemic
sclerosis (Naik et al., 2010). However, the side effects of PA
treatment are numerous. The main concern is the worsening
in neurologically presenting patients, who do not recover even
with PA discontinuation (Brewer et al., 1987; Kalita et al., 2014).
Neurologic deterioration has been reported in 50% of WD
patients with neurologic presentation. Many have recommended
avoiding prescription of PA when less harmful drugs are
available, such as zinc and trientine. In Lebanon, both zinc and
trientine, if available, are quite expensive leaving clinicians with
one option, PA prescription.
Therefore, this study was undertaken to explore the safety of
this de-coppering drug; more specifically it aimed at investigating
the in vitro effect of PA and Cu on neural cell lines. To mimic the
condition ofWD patients, cells were treated for 24 h with varying
concentrations with Cu, PA or both.
The choice of PA concentration (250µM), was not arbitrary,
but based on previous studies, on human leukemia and breast
cancer cells, reporting non-toxicity of PA at 200–500µM (Gupte
and Mumper, 2007a,b). Likewise, the Cu concentration used was
chosen relative to reported approximate range of physiological
Cu concentrations (70µM and 100µM) in cerebrospinal fluid
and synaptic cleft respectively (Kardos et al., 1989; Opazo et al.,
2014).
Initially, MTT assay was used to determine the IC50 (50µM)
in Cu-treated U251 cells (Supplementary Figure 1). However,
MTT viability results were discordant with those using trypan
blue exclusion assay (Figure 2). While the latter is a qualitative
assay determining the number of viable cells based on the cell
membrane integrity (Strober, 2001), the MTT assay measures
mitochondrial function by monitoring the effect of Cu, on the
activity of mitochondrial dehydrogenase (van Meerloo et al.,
2011). Thus, this discordance may be attributed to the possible
interference of Cu with the MTT assay. Previous in vivo
and in vitro studies have reported inhibition of the activity
of the mitochondrial NADH-dependent dehydrogenases by
Cu without leading to cell death (Sheline and Choi, 2004).
No major effect on the viability of PA treated U251 cells
was obtained using either assay. Co–treatment however, with
Cu-PA (50–250µM) decreased significantly and to the same
extent the viability in either assay, suggesting sensitivity of
U251 cells to Cu-PA co-treatment, but not to Cu or PA
alone.
Our findings are similar to previous studies which reported:
(a) small decrease in cell proliferation of cultured rabbit articular
chondrocytes treated with either CuSO4 or D-PA but marked
increase in the extent of growth inhibition of cells treated with
D-PA in association with copper (Clain et al., 1988); and (b)
cytotoxicity of Cu-PA (10 ≤ 400µM) on human breast cancer
MCF-7 and BT474 cells, and human leukemia HL-60 cells (Gupte
and Mumper, 2007a).
Consistent with the obtained results, we observed no
morphological changes in PA or Cu treated cells. However,
co-treatment with Cu-PA induced the loss of the distinctive
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FIGURE 7 | Western blot analysis of alpha fodrin cleavage in Cu, and/or
PA treated U251 cells. Representative SDS-PAGE image of U251 protein
lysate (75µg) Cu-PA treated clearly shows the 150 KDa band indicative of
proteolytic cleavage and characteristic of apoptosis. No cleavage products
were detected in Cu or PA treated cells (Supplementary Figure 2).
elongated morphology of U251 cells into rounded shape.
For further assessment of the morphological changes and
membrane derangement, we examined whether necrosis occurs
following the different treatments by measuring the LDH level
released (Vairetti et al., 2005; Chan et al., 2013). In our study,
no significant release of LDH into the media of cultured
cells was detected in any of treatments. These findings are
in congruence with those reporting 10% LDH release from
PC12 cells treated for 48 h with 500µM Cu (10-fold the
concentration used in the current study) (Belyaeva et al.,
2012).
Copper (Cu) is an important component of electron
transport chain protein complexes, such as cytochrome c
oxidase (Horn and Barrientos, 2008). Previous study had
reported impaired mitochondrial enzymatic activities in
ATP7B−/− animals with apparent clinical manifestations of
WD. In addition, isolated liver mitochondria treated with Cu
chelators showed structural and functional changes (Zischka
et al., 2011). Although intracellular level of copper was not
determined in this study, mobilization of intracellular copper
sites of mitochondria would perturb copper level and derange
mitochondrial function (Bush, 2000). Qualitative assessment
of the coupling state of the mitochondrial membrane potential
(Mito JC-1 kit) showed no effect on membrane potential
following treatment of U251 cells with Cu while PA induced
partial depolarization. However, the co-treatment with Cu-
PA resulted in complete depolarization. This suggests that
dissipation of the mitochondrial membrane potential is
not resulting solely from the possibility of Cu mobilization
induced by PA, but from a possible toxic intermediate
or component derived or resulted from PA interaction
with Cu.
Mitochondrial dysfunction may induce oxidative stress that
results from generation of ROS and/or depletion of GSH
(Gyulkhandanyan et al., 2003). In this study, we obtained
no significant variation in ROS or GSH level in Cu or PA
treated U251 cells, in concordance with a previous study on
astrocytes reporting that copper exerted no significant changes
in ROS and GSH levels and mitochondrial membrane potential
(Gyulkhandanyan et al., 2003; Scheiber and Dringen, 2011).
Having stronger anti-oxidative potential than neurons, astrocytes
may protect them from compound induced oxidative stress
(Desagher et al., 1996; Scheiber andDringen, 2011; Dringen et al.,
2013). However, increased oxidative damage in neuronal P19 and
PC12 cells occurred at a Cu concentration greater than 0.5 mM
(Jazvinscak Jembrek et al., 2014). On the other hand, the obtained
depletion in GSH level in U251 cells co-treated with Cu-PA, is
in line with generated ROS and depolarization of mitochondrial
membrane potential. In one study, ROS production was
insignificant with either PA or CuSO4 treated leukemia/breast
cancer cells; while co-treatment with Cu-PA exhibited a
concentration-dependent H2O2-mediated cytotoxicity with a
concomitant decrease in intracellular GSH levels (Gupte and
Mumper, 2007a). Impairment in cellular defense mechanisms
against ROS causes oxidative stress induced neurodegenerative
disorders. These include endogenous enzymes (Superoxide
dismutase, Glutathione peroxidase), Low molecular weight
antioxidants (glutathione, tocopherols, ascorbic acid, Vitamin
A, lipoic acid) and precursors of endogenous antioxidants
(NAC) (Gilgun-Sherki et al., 2001). Previous studies reported
the considerable depletion ascorbic acid level and compromised
antioxidant status in plasma of untreated WD patients (Ogihara
et al., 1995; Attri et al., 2006). Several In vivo studies have
alluded to the protective effects of the antioxidants, such as
lipoic acid (Yamamoto et al., 2001), Vitamin E (Yamazaki et al.,
1993; Fryer, 2009), ascorbic acid and thioredoxin (Hawkins et al.,
1995) against Cu-induced hepatitis in Long Evan Cinnamon rats
an animal model of WD. Other in vitro studies demonstrated
the biochemical role of mitochondrial enzyme cofactors in
attenuating copper induced death (Sheline et al., 2002); for
instance the beneficial role of thiamine supplementation has been
widely reviewed and documented (Luong and Nguyen, 2013).
In addition the decrease in GSH and protein thiol levels was
reported to enhance the pro-apoptotic conditions and oxidative
stress in hepatocytes and neurons of WD rodent model (Samuele
et al., 2005).
Starkebaum and Root (1985) reported that during chelation,
reduction of Cu2+–Cu+ generates PA (thiyl) radicals.
Regeneration of Cu2+occurs at the expense of the consecutive
reduction of oxygen by Cu+ into superoxide (O.−2 ) radical,
and then hydrogen peroxide (H2O2). Figure 12 presents the
different steps leading to the net PA oxidation that results in
H2O2 generation (Figure 12), at a molar ratio of 2:1 (Starkebaum
and Root, 1985). To examine whether cytotoxicity of Cu-PA is
mediated by H2O2 we studied the potential role of antioxidants
(NAC, Trolox, and catalase) in reversing Cu-PA toxicity.
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FIGURE 8 | Protective effect of antioxidants: NAC (5 mM), Trolox (100µM), and catalase (500U) on: (A) viability and (B) ROS generation in Cu-PA treated
U251 cells. Viability was determined using MTT cell proliferation assay, whereas level of ROS generated was determined using NBT reduction assay. Data presented is
the mean ± SEM of 6-determinations from 3-different experiments. Asterisks on bars represent inter-categorical statistical significance with Cu-PA category, and
those drawn upwards represent significance relative to the control. (*) and (***) correspond to P < 0.05 and 0.001 respectively.
Co-treatment with catalase, a key antioxidant enzyme specifically
responsible for decomposition of H2O2 (Marklund et al., 1982),
completely restored the viability and decreased oxidative stress
level in Cu-PA co-treated cells. However, NAC and Trolox were
less protective than catalase. These results confirm that H2O2 is
the culprit molecule mediating oxidative stress and apoptosis in
Cu-PA treated cells.
H2O2 is a major oxidant known to cause neuronal injury
(Coombes et al., 2011). The increase in oxidative stress alters
functions of glial cells contributing thus to the pathogenesis of
neurodegenerative diseases as well as to the selective vulnerability
of neurons (Dringen, 2000). One biochemicalmarker of oxidative
stress is the level of GSH, the decrease of which was shown
to trigger apoptotic events (Franco and Cidlowski, 2009) that
can be verified using flow cytometry. Comparing % distribution
of cell cycle phases between control and PA or Cu treated
U251 cells, we found no significant difference, confirming
the attribution of the decrease in cell viability of Cu-treated
cells (MTT assay) to a decrease in the dehydrogenase activity.
However, U251 cells co-treated with Cu-PA caused a 99%
increase in subG0 phase, compared to 1% in control cells,
indicating DNA fragmentation (Sedlak et al., 1999) leading
to cell death by apoptosis or necrosis (Higuchi, 2003). The
depletion of GSH level and the absence of LDH release in
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FIGURE 9 | Dose-dependent effect of catalase enzyme on viability (A) and ROS generation (B) in Cu-PA treated U251 cells. Viability was assessed by MTT cell
proliferation assay, whereas ROS generation was determined by NBT reduction assay. Data presented is the mean ± SEM of 6-determinations from 3-different
experiments. Asterisks on bars represent inter-categorical statistical significance (each category with the preceding one), and those drawn upwards represent
significance relative to the control. (***) correspond to P < 0.001.
Cu-PA treatedU251 cells supports apoptosis rather than necrosis.
A hallmark of apoptosis includes the activation of proteases
that cleave structural proteins, initiating a cascade of events.
More specifically the proteolysis of α-fodrin by caspase-3 and
calpains contributes to structural rearrangements including
blebbing during apoptosis (Martin et al., 1995; Janicke et al.,
1998; Kahaly et al., 2005). Using western blot analysis, we
identified a 150 KDa fragment, the calpain-dependent cleavage
of α-fodrin in Cu-PA co-treated U251 cells (Supplementary
Figure 2).
Ceruloplasmin, the main transporter of copper in blood, is
an acute phase reactant protein, the serum concentration of
which increases during inflammation or trauma (Gitlin, 1988).
It is predominantly synthesized in the liver and is also expressed
in various tissues including spleen, lungs, and brain (Aldred
et al., 1987). Cp is expressed in 2 isoforms as a secreted form or
Glycosylphosphatidylinositol-Cp anchored to plasma membrane
(Patel et al., 2000). In the current study, we reported that Cp
expression increased by 67% in Cu-treated U251, consistent with
the ability of astrocytes to recognize, transport and store nutrients
(Scheiber et al., 2014). Treatment with PA exerted no effect;
whereas co-treatment with Cu-PA decreased its expression by
60%. Since similar results were not obtained with PA treatment
alone, the decrease of Cp expression by Cu-PA may not be
due to mobilization of intracellular Cu stores. Instead, this
could be the result of Cu-catalyzed PA oxidation generating
extracellular H2O2 that has been reported to decrease the Cp
level through an mRNA decay mechanism (Tapryal et al., 2009).
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FIGURE 10 | Effect of CuSO4 and/or PA treated U251 cells on ceruloplasmin expression level. Ceruloplasmin expression was determined using western blot
analysis on protein lysates of different cell treatments. Fold expression was determined relative to the control following quantitative assessment of bands using Image
J. Expression level of treated and control samples normalized to their respective GAPDH. Asterisks on bars represent inter-categorical statistical significance (each
category with the preceding one), and those drawn upwards represent significance relative to the control. (*), and (***) correspond to P < 0.05, 0.01, and 0.001
respectively. Image is representative of 2 experiments.
This poses a question regarding the other consequences of the
lifelong management of WD patients using copper chelators. Cp
belongs to multi-copper oxidase family (Cha and Kim, 1999)
with ferroxidase activity implicated in iron loading onto serum
transferrin, as well as in iron homeostasis (Okamoto et al., 1996).
One possible consequence of Cu chelation is impairment in iron
loading which is copper-Cp dependent preventing the oxidation
of Fe2+ to Fe3+ leading ultimately to iron deposition. The piled
Fe2+ in the presence of the Cu-PA induced generated H2O2
will produce hydroxyl and superoxide radicals through fenton
reactions eventually leading to cell death (Agil et al., 1995).
To examine whether the effects of Cu and/or PA are
specific to U251 cells only, we used PC12 cells that are
widely accepted as model system for: neuronal differentiation,
neurosecretion, neuronal injury (Pera et al., 2013). Furthermore,
PC12 (differentiated and undifferentiated) were used to assess
neurotoxicity underlying degenerative disorders, following their
exposure to necrotic insult (Jiang et al., 2014), as well as apoptosis
during brain injury (Ballesteros et al., 2007; Minambres et al.,
2008). In a recent report, PC12 were also used as a model to study
Cu metabolism during PC12 differentiation into neurons (Ogra
et al., 2016).
In our study, whereas Cu or PA treated PC12 cells had
similar effects to those of U251 cells, Cu-PA treated PC12
exerted a milder effect: generated ROS (16%), increase in sub
G0 phase (12%), LDH–release (16%) and a partial depolarization
of mitochondria. The resistance of PC12 to the co-treatment
is unexplainable and may possibly be attributed to species
difference, being derived from rats, PC12 cells sensitivity may
differ from human U251 cells. A plausible reason may be
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FIGURE 11 | Effect of CuSO4 and/or PA treated PC12 cells on: (A) viability using MTT assay and Trypan blue exclusion test, (B) ROS level using NBT reduction
assay, (C) LDH release using cytotoxicity detection kit, (D) mitochondrial membrane potential using Mito PT-JC1 assay (a) control; (b) 50µM CuSO4; (c) 200µM
CuSO4; (d) 250µM PA; and (e) Cu-PA, treated PC12 cells, and (E) Cp expression level using western blot analysis. Data presented is the mean ± SEM of:
15-determinations from 5-different MTT experiments and 3-determinations from 3-different Trypan blue exclusion experiments; 12-determinations each from
4-different NBT reduction experiments and LDH release assays and of 3-determinations from 3-different Western Blot analysis. Asterisks on bars represent
inter-categorical statistical significance relative to a control. (***) correspond to P < 0.001.
attributed to the undifferentiated state of the PC12 cells, although
they have been useful in identifying protein fragments underlying
neuronal dysfunction. The effect of Cu-PA was not limited
to glioblastoma U251 cells but is extended to differentiated
neuroblastoma SH-SY5Y cells identifying thus neuronal cells as
potential targets for Cu-PA. However, SH-SY5Y cells differed
from Glioblastoma U251 cells, in: (a) being more sensitive
(decreased in viability) to free copper or PA but as sensitive to
Cu-PA co-treatment and (b) the level of generated ROS post Cu-
PA treatment was not remarkably different fromCu or PA treated
cells. Our finding are in line with a previous study reporting
mitochondrial dehydrogenase inhibition in Cu induced toxicity
of neuroblastoma cell line (Arciello et al., 2005). Hence, both
cell lines may serve as potential target to Cu-PA. Many studies
have reported the involvement of diverse neural cells including
neuronal and glial cells in neurological disorders induced in
patients with WD (Horoupian et al., 1988; Lewandowska et al.,
2004; Merker et al., 2005).
In this study, we investigated the sensitivity of U251 cells
to Cu-PA treatment at a Cu concentration below the toxic
levels of Cu (500 µM). Cu-PA co-treatment triggers remarkable
extracellular generation of H2O2 which permeates the plasma
membrane of U251 cells causing a decrease in Cp expression by
mRNA degradation, leading to a decrease in glutathione level,
an increase in oxidative stress by Fenton reactions. This may
initiate a cascade of events eventually leading to apoptosis, as
evidenced by the dissipation of the mitochondrial membrane
potential, DNA fragmentation, and cleavage of apoptotic marker
α-fodrin (Figure 12).
One possible explanation for the deterioration of the
neurological symptoms may be the low activity of catalase in
the brain. Both gray and white matters of the human brain
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FIGURE 12 | Schematic Diagram summarizing the effect of Cu-PA treatment on neural cells H2O2 generation increases following Cu-PA treatment on
U251 Glial cells. Entry of H2O2 into the cells increases oxidative stress intracellularly. Alternatively, it mobilizes intracellular copper leading to a decrease in CP
expression. Decrease in level of incorporated Cp copper would decrease ferroxidase activity involved in iron loading onto iron binding/transporting proteins. The
increase in Fe3+ in presence of H2O2 generates hydroxyl radicals and increases ROS level leading to a decrease in GSH level. Consequences of the increased
oxidative stress are: dissipation of mitochondrial membrane potential that triggers apoptotic events; increase in SubG0 phase /DNA fragmentation; and activation of
caspases causing proteolytic cleavage of α-fodrin eventually leading to cell death of U251 glial cells. Catalase enzyme protected completely treated U251 cells
whereas NAC and Trolox were partially protective.
have immeasurable levels of catalase (Marklund et al., 1982;
Baydas et al., 2002). For this reason, we propose that antioxidant
supplements be part of the therapeutic regimen with PA treated
WD patients with neurological presentation.
There are several limitations to our study. These include
the use of human cancer cells (U251 and SH-SY5Y) which
might have normal copper metabolism as well as the use
of immortalized rat derived PC12 as normal cells. It is
recommended that future studies addressing the effect of Cu-PA
be performed in vivo or on isolated primary neuronal cells.
To conclude, our findings identify U251 cells with both
positive (preventive) and negative (toxic) roles. Being the first
target and primary site of exposure to external factors and
drugs (Scheiber et al., 2014), the apoptotic cell death of the
astrocytes provides a mechanism (remarkable increase in ROS)
that might protect the underlying neuronal cells. MRI studies
reported diffusion restriction and T2 hyperintensity in the white
matter of neurologic WD patients caused from damaged glial
system with compromised ability to clear oxidative stress (Kalita
et al., 2014; Ranjan et al., 2015). The demonstrated toxicity
in U251 and SH-SY5Y cells co-treated with Cu-PA may shed
some light on one of the possible underlying mechanisms that
worsens the manifestations of WD patients with neurologic
manifestations. In a copper rich environment, such as the
one characterizing WD, the expected response (generation of
H2O2) would be exaggerated. In addition, our findings pose an
important question on the consequence of PA treatment on Fe
homeostasis, and possible Fe deposition, which might require
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new modalities in managing side effects of the lifelong treatment
of WD patients.
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